Nimbex is a drug owned by Abbvie Inc. It is protected by 1 US drug patent filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Sep 26, 2012. Details of Nimbex's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US5453510 | Neuromuscular blocking agents |
Sep, 2012
(12 years ago) |
Expired
|
US patents provide insights into the exclusivity only within the United States, but Nimbex is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Nimbex's family patents as well as insights into ongoing legal events on those patents.
Nimbex's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Nimbex's generic launch date based on the expiry of its last outstanding patent is estimated to be Sep 26, 2012 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Nimbex Generic API suppliers:
Cisatracurium Besylate is the generic name for the brand Nimbex. 16 different companies have already filed for the generic of Nimbex, with Piramal Critical having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Nimbex's generic
How can I launch a generic of Nimbex before its drug patent expiration? :
You can seek FDA approval to launch a generic drug before the expiration of Nimbex's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the Nimbex's sponsor is invalid, unenforceable, or will not be infringed by your generic product.
Given below are the details of the already filed Para IV certificates on Nimbex -
| Strength | Submission Date | ANDA(s) Filed | First applicant approval | Last patent expiry | 180 day status |
|---|---|---|---|---|---|
| 2 mg/mL, 10 mL vial | 12 Aug, 2009 | 1 | 03 Feb, 2012 | 26 Sep, 2012 | Eligible |
| 2 mg/mL, 5 mL vial and 10 mg/mL, 20 mL vial | 04 Aug, 2009 | 1 | 03 Feb, 2012 | 26 Sep, 2012 | Eligible |
Alternative Brands for Nimbex
Nimbex which is used for muscle relaxation during surgery., has several other brand drugs in the same treatment category and using the same active ingredient (Cisatracurium Besylate). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | Treatment Area | ||
|---|---|---|---|---|
| Abbvie |
| |||
Apart from brand drugs containing the same ingredient, some generics have also been filed for Cisatracurium Besylate, Nimbex's active ingredient. Check the complete list of approved generic manufacturers for Nimbex
About Nimbex
Nimbex is a drug owned by Abbvie Inc. It is used for muscle relaxation during surgery. Nimbex uses Cisatracurium Besylate as an active ingredient. Nimbex was launched by Abbvie in 1995.
Approval Date:
Nimbex was approved by FDA for market use on 15 December, 1995.
Active Ingredient:
Nimbex uses Cisatracurium Besylate as the active ingredient. Check out other Drugs and Companies using Cisatracurium Besylate ingredient
Treatment:
Nimbex is used for muscle relaxation during surgery.
Dosage:
Nimbex is available in injectable form for injection use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| EQ 2MG BASE/ML | INJECTABLE | Discontinued | INJECTION |